AzTrials
AzTrials

Intraabdominal HypertensionNCT06221293

Correlation Between Intra-abdominal Pressure, Biomarkers of Bacterial Translocation and Intestinal Wall Damage

An observational study of Intraabdominal Hypertension and Multi-Organ Disorder, run by Karaganda Medical University at 5 sites in Kazakhstan.

Unknown status

Status not confirmed. The sponsor has not verified this record for over two years, so it may be out of date.

Official record
Search all trials

Trial summary

Main scientific hypotheses of the project: 1. The level of intestinal microflora translocation markers and biomarkers of intestinal wall damage the in the blood serum correlates with the level of intra-abdominal pressure, regardless of the genesis of intra-abdominal hypertension. 2. Read more about this study

Who is it for?
Ages 18 to 90 yearsHealthy volunteers can take part
What is being tested?
immunoenzyme analysis
How many people
180 participants
Where
5 sitesKazakhstan
Study dates
1 Mar 2023to 27 Dec 2025
How long will I take part?
10 Days
Phase
Observational
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 to 90 years
  • All sexes
  • Healthy volunteers accepted
  • Adult, Older adult

Study population: Patients over 18 years of age with multi-organ dysfunction syndrome and increased intra-abdominal pressure

Who may be able to join

  • registered multiple organ dysfunction syndrome of various genesis
  • over 18 years of age.

Who cannot join

  • age under 18
  • pregnancy
  • HIV infection

Trial locations and contacts

5 sites in 1 country.

5 sites in 1 country

Kazakhstan5 sites
  • Karaganda Medical University

    Karaganda, 1000000

  • Clinic of the Medical University of Karaganda

    Karaganda, 100000

  • Multidisciplinary hospital No. 1

    Karaganda, 100000

  • Multidisciplinary Hospital No. 3

    Karaganda, 100000

  • Regional Clinic Hospital

    Karaganda, 100000

Other trials in Kazakhstan

About this study

Official title: Study of the Relationship Between Intra-abdominal Pressure, Biomarkers of Bacterial Translocation and Intestinal Wall Damage in Multiple Organ Dysfunction Syndrome.

Main scientific hypotheses of the project:

  1. The level of intestinal microflora translocation markers and biomarkers of intestinal wall damage the in the blood serum correlates with the level of intra-abdominal pressure, regardless of the genesis of intra-abdominal hypertension.
  2. The critical levels of intestinal microflora translocation markers and biomarkers of the intestinal wall damage can be used for predicting an unfavorable outcome in the multiple organ dysfunction syndrome.
  3. The revealed critical level of intra-abdominal pressure is an additional prognostic sign in assessing the course of the multiple organ dysfunction syndrome.
Read more

. Project objectives:

  1. To evaluate the indicators of biomarkers of translocation of the intestinal microflora and biomarkers of the intestinal wall damage in the systemic circulation during the development and course of the syndrome of multiple organ dysfunction. Based on the obtained critical levels of markers of translocation of the intestinal microflora and markers of the intestinal wall damage, it will be possible to predict adverse outcomes in patients with multiple organ dysfunction syndrome.
  2. To identify differences in the level of markers of bacterial translocation of the intestinal microflora and the level of markers of the intestinal wall damage in patients with intra-abdominal hypertension. In patients with multiple organ dysfunction syndrome, the levels of biomarkers of bacterial translocation of the intestinal microflora and biomarkers of intestinal wall damage in the blood serum correlate with intra-abdominal pressure indicators, regardless of the etiology of intra-abdominal hypertension.
  3. Assess the impact of the level of intra-abdominal pressure on the development and course of the syndrome of multiple organ dysfunction. To assess the course of the syndrome of multiple organ dysfunction, an additional prognostic marker is the determination of the critical level of intra-abdominal pressure.
  4. Determine the critical levels of biomarkers of intestinal microflora translocation and biomarkers of intestinal wall damage to predict the outcome of diseases accompanied by the development of multiple organ dysfunction syndrome. The obtained critical levels of biomarkers of translocation of the intestinal microflora and biomarkers of the intestinal wall damage will be significant indicators in the syndrome of multiple organ dysfunction for predicting an unfavorable outcome.
Read the detailed description

The aim of the project is to evaluate the impact of intra-abdominal hypertension, biomarkers of bacterial translocation and biomarkers of intestinal wall damage on the course and outcomes of the disease in patients with multiple organ dysfunction.

Today the intestinal microflora translocation is considered as one of the key mechanism of an enhanced systemic inflammatory response that leads to multiple organ dysfunction. In the intensive care unit, in patients in serious condition changes in various body systems develop, including the immune system reacts with the production of endogenous pro-inflammatory mediators, and due to microcirculation disorders, ischemia and hypoxia of the intestinal wall, aggravated by an increase in intra-abdominal pressure, its permeability increases, its barrier function is impaired. As a result, bacteria and/or their endotoxins penetrate the damaged intestinal barrier and further enhance the immune response, which becomes systemic and ultimately leads to multiple organ dysfunction. When the described processes occur, the assessment of splanchnic blood flow becomes especially relevant.

sCD14-ST (presepsin) and LBP (lipopolysaccharide-binding protein) are being studied as biomarkers of bacterial translocation, and I-FABP (Intestinal fatty-acid binding protein), REG3α (regenerating islet-derived protein-3α) and Zonulin (zonulin) are being studied as biomarkers of intestinal wall injury.

The interaction of the macrophage membrane protein CD14 with peptidoglycans of gram-positive and lipopolysaccharides of the walls of gram-negative bacteria leads to the production of sCD14-ST. Presepsin is a biomarker for the early phase of sepsis and a predictor of outcome in septic patients.

LBP increases the sensitization of receptors of cells of the immune system: macrophages, monocytes, neutrophils to bacterial lipopolysaccharide, which leads to the activation of the immune response by releasing pro-inflammatory mediators. LBP appears to be an effective biomarker for bacterial translocation and the development of septic complications.

I-FABP is a protein that is located on the villi of mature enterocytes. An increase in the level of I-FABP in the blood serum is associated with a violation of the permeability of the intestinal wall, which has been proven in a number of studies.

Paneth cells secrete the antimicrobial protein REG3α into the intestine, and in case of the intestinal wall damage, it moves into the bloodstream. This protein is a reliable biomarker of intestinal wall damage.

Zonulin is a protein that playing a significant role in intestinal wall permeability. It opens the intracellular tight junctions between the cells of the duodenum and small intestine, which leads to an increase in the permeability of the intestinal wall. Therefore, serum zonulin is a marker of dysfunction and increased permeability of the intestinal barrier.

In the databases of publications (Scopus, Web of Science) there were no articles on the study of the relationship between the level of biomarkers of intestinal translocation, the level of biomarkers of the intestinal wall damage and the level of intra-abdominal pressure in patients with multiple organ dysfunction syndrome. This study will allow a more in-depth study of the pathogenesis of intestinal microflora translocation in patients with multiple organ dysfunction syndrome, and will also allow using the results obtained to predict the course of this condition.

Detection of blood serum biomarkers sCD14-ST, LBP, I-FABP, REG3α and Zonulin will be performed by enzyme immunoassay. The level of intra-abdominal pressure will be measured by the method of tonometry in the bladder through a urethral catheter using a portable invasive low pressure meter (IIND - 500/75) by Triton-Electronics LLC.

The expected scientific results of studying the relationship between intra-abdominal pressure, the phenomenon of translocation of intestinal microflora into the systemic circulation with the pathogenesis and dynamics of the development of multiple organ dysfunction syndrome will have an impact on the further improvement of the treatment tactics of this pathology. Innovative methods for diagnosing the phenomenon of intestinal microflora translocation will have a positive effect on the development of laboratory diagnostics and science in Kazakhstan.

Revealing of relationships between intestinal microflora translocation biomarkers, biomarkers of the intestinal wall damage and changes in intra-abdominal pressure will allow a more in-depth study of the pathogenetic mechanisms in the development and course of the multiple organ dysfunction syndrome, depending on its genesis, which will allow using the results obtained to predict the outcomes of this syndrome.

2.2. The aim of the project is to evaluate the impact of intra-abdominal hypertension, biomarkers of bacterial translocation, and biomarkers of the intestinal wall damage on the course and outcomes of the disease in patients with multiple organ dysfunction.

2.3. Project objectives:

  1. To evaluate the indicators of biomarkers of translocation of the intestinal microflora and biomarkers of the intestinal wall damage in the systemic circulation during the development and course of the syndrome of multiple organ dysfunction. Based on the obtained critical levels of markers of translocation of the intestinal microflora and markers of the intestinal wall damage, it will be possible to predict adverse outcomes in patients with multiple organ dysfunction syndrome.
  2. To identify differences in the level of markers of bacterial translocation of the intestinal microflora and the level of markers of the intestinal wall damage in patients with intra-abdominal hypertension. In patients with multiple organ dysfunction syndrome, the levels of biomarkers of bacterial translocation of the intestinal microflora and biomarkers of intestinal wall damage in the blood serum correlate with intra-abdominal pressure indicators, regardless of the etiology of intra-abdominal hypertension.
  3. Assess the impact of the level of intra-abdominal pressure on the development and course of the syndrome of multiple organ dysfunction. To assess the course of the syndrome of multiple organ dysfunction, an additional prognostic marker is the determination of the critical level of intra-abdominal pressure.
  4. Determine the critical levels of biomarkers of intestinal microflora translocation and biomarkers of intestinal wall damage to predict the outcome of diseases accompanied by the development of multiple organ dysfunction syndrome. The obtained critical levels of biomarkers of translocation of the intestinal microflora and biomarkers of the intestinal wall damage will be significant indicators in the syndrome of multiple organ dysfunction for predicting an unfavorable outcome.
  5. Scientific novelty and significance of the project Multiple Organ Dysfunction Syndrome (MODS) is a potentially reversible physiological disorder involving two or more organ systems not involved in the process resulting in intensive care unit (ICU) hospitalization. MODS results in longer ICU stays and, in severe cases, leads to high mortality (27%-100%).

In this scientific project, it is planned to study the levels of biomarkers of bacterial translocation (sCD14-ST, LBP) levels of biomarkers of intestinal wall damage (I-FABP, REG3α and Zonulin) and intra-abdominal pressure in patients with multiple organ dysfunction syndrome.

The interaction of the macrophage membrane protein CD14 with peptidoglycans of gram-positive and lipopolysaccharides of the walls of gram-negative bacteria leads to the production of sCD14-ST . Presepsin is a biomarker for the early phase of sepsis and a predictor of outcome in septic patients.

LBP increases the sensitization of receptors of cells of the immune system: macrophages, monocytes, neutrophils to bacterial lipopolysaccharide, which leads to the activation of the immune response by releasing pro-inflammatory mediators. LBP appears to be an effective biomarker for bacterial translocation and the development of septic complications.

I-FABP is a protein that is located on the villi of mature enterocytes. An increase in the level of I-FABP in the blood serum is associated with a violation of the permeability of the intestinal wall, which has been proven in a number of studies.

Paneth cells secrete the antimicrobial protein REG3α into the intestine, and in case of the intestinal wall damage, it moves into the bloodstream. This protein is a reliable biomarker of intestinal wall damage and bacterial translocation.

Zonulin first described like it is a protein that playing a significant role in intestinal wall permeability. It opens the intracellular tight junctions between the cells of the duodenum and small intestine, which leads to an increase in the permeability of the intestinal wall. Therefore, serum zonulin is a marker of dysfunction and increased permeability of the intestinal barrier.

  1. Research methods The type of research being conducted is fundamental research. The design of the study complies with the principles of the Declaration of Helsinki of the World Medical Association and was approved by the Local Commission on Bioethics of the NJSC KMU. Clinical bases in Karaganda, where biological material will be taken: Multidisciplinary Hospital No. 1, Regional Clinical Hospital, Clinic of Medical University. Laboratory research will be carried out on the basis of the Research Laboratory of the Institute of Life Sciences of the NJSC KMU.

Main scientific hypotheses of the project:

  1. The level of intestinal microflora translocation markers and biomarkers of intestinal wall damage the in the blood serum correlates with the level of intra-abdominal pressure, regardless of the genesis of intra-abdominal hypertension.
  2. The critical levels of intestinal microflora translocation markers and biomarkers of the intestinal wall damage can be used for predicting an unfavorable outcome in the multiple organ dysfunction syndrome.
  3. The revealed critical level of intra-abdominal pressure is an additional prognostic sign in assessing the course of the multiple organ dysfunction syndrome.

Research material. It is planned to study bacterial translocation biomarkers (sCD14-ST, LBP), biomarkers of intestinal wall damage (I-FABP, REG3α and Zonulin) in blood serum and measure intra-abdominal pressure in 180 patients with multiple organ dysfunction syndrome.

Measurement of intra-abdominal pressure will be carried out in patients with multiple organ dysfunction syndrome through a urethral catheter using a portable electronic device "ILPM - 500/75" (invasive low-pressure meter) manufactured by LLC "Triton - ElectronicS", Yekaterinburg, RF.

Technique for measuring intra-abdominal pressure: 50 ml of warm sterile isotonic sodium chloride solution is injected into the previously emptied bladder through a Foley catheter with an inflated balloon using a syringe without a needle. The urethral catheter is attached to the measuring device. With the valve of the urethral catheter closed, a zero value is set, after which the valve of the catheter is opened and the intra-abdominal pressure is recorded according to the indication on the display of the device

Risks and their solutions:

  1. With an increase in prices for the necessary reagents and materials due to the constant change in the exchange rate, most of the purchase will be carried out in the 1st year of the project implementation. Reducing the number of studies conducted while maintaining statistical significance without significant losses for the project.
  2. When changing the place and dates of congresses and conferences with a change in travel costs, there will be changes in the number of business travelers.
Being tested
immunoenzyme analysis
Keywords
bacterial translocation, presepsin, intraabdominal hypertension, multi-organ disorder, I-FABP, REG3a, Zonulin
Medical subject headings
Intra-Abdominal Hypertension

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • immunoenzyme analysisDiagnostic test

    immunoenzyme analysis with EVOLIS system

Study groups in NCT06221293
Study groupRoleWhat they receive
Group 1the first group consists of patients with increased abdominal pressure, signs of multi-organ failure with a fatal outcome
Receives: Diagnostic Test: immunoenzyme analysis
Group 2the second group consists of patients with increased abdominal pressure, signs of multi-organ failure without death
Receives: Diagnostic Test: immunoenzyme analysis

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Detection of biomarkers of translocation

    To evaluate the indicators of biomarkers of translocation of the intestinal microflora and biomarkers of the intestinal wall damage in the systemic circulation during the development and course of the syndrome of multiple organ dysfunction. Based on the obtained critical levels of markers of translocation of the intestinal microflora and markers of the intestinal wall damage, it will be possible to predict adverse outcomes in patients with multiple organ dysfunction syndrome.

    Measured: 3-10 days

Secondary outcomes (1)
  1. The differences between level of bacterial translocation and level of markers of the intestinal wall damage with intraabdominal hypertension

    To identify differences in the level of markers of bacterial translocation of the intestinal microflora and the level of markers of the intestinal wall damage in patients with intra-abdominal hypertension. In patients with multiple organ dysfunction syndrome, the levels of biomarkers of bacterial translocation of the intestinal microflora and biomarkers of intestinal wall damage in the blood serum correlate with intra-abdominal pressure indicators, regardless of the etiology of intra-abdominal hypertension.

    Measured: 3-10 days

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted24 Jan 2024
  2. Study start1 Mar 2023
  3. Primary completion25 Dec 2025 (estimated)
  4. Study completion27 Dec 2025 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Observational
Observational model
Case crossover
Time perspective
Prospective
Enrolment
180 participants (estimated)
Target duration
10 Days
IDs, dates and publications
ClinicalTrials.gov ID
NCT06221293
Sponsor's protocol ID
ИРН АР 19677271
Other IDs
ИРН AP19677271
Status last verified
Apr 2024
First submitted
15 Jan 2024
Last updated
19 Apr 2024
Results posted
No
Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
No

Publications

  • Turgunov Y, Ogizbayeva A, Akhmaltdinova L, Shakeyev K. Lipopolysaccharide-binding protein as a risk factor for development of infectious and inflammatory postsurgical complications in colorectal cancer paients. Contemp Oncol (Pozn). 2021;25(3):198-203. doi: 10.5114/wo.2021.110051. Epub 2021 Oct 14.

    PubMed 34729040
  • Shakeyev K, Turgunov Y, Ogizbayeva A, Avdiyenko O, Mugazov M, Grigolashvili S, Azizov I. Presepsin (soluble CD14 subtype) as a risk factor for the development of infectious and inflammatory complications in operated colorectal cancer patients. Ann Coloproctol. 2022 Dec;38(6):442-448. doi: 10.3393/ac.2022.00115.0016. Epub 2022 Apr 4.

    PubMed 35368178
  • Amanova DY, Lavrinenko AV, Kaliyeva DK, Matyushko DN, Ivachyov PA, Turgunov YM. Comparative Evaluation of Translocation of GFP Producing Escherichia coli Strains in Acute Intestinal Obstruction. Bull Exp Biol Med. 2019 Sep;167(5):660-662. doi: 10.1007/s10517-019-04593-y. Epub 2019 Oct 17.

    PubMed 31625067
  • Ivachyov P, Amanova D, Akhmaltdinova L, Koishibayev Z, Turgunov E. [COMPARISON OF DYNAMICS OF LEVEL OF PROCALCITONIN, LIPOPOLYSACCHARIDE BINDING PROTEIN AND INTERLEUKIN-6 IN BLOOD SERUM OF EXPERIMENTAL ANIMALS AT STRANGULATED AND OBTURATIVE INTESTINAL OBSTRUCTION]. Georgian Med News. 2020 Jun;(303):173-177. Russian.

    PubMed 32841201

Questions about this trial

What is this clinical trial studying?

An observational study of Intraabdominal Hypertension and Multi-Organ Disorder, run by Karaganda Medical University at 5 sites in Kazakhstan.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 2 inclusion and 3 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: status not confirmed, as of the sponsor's last update on 19 Apr 2024. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 5 sites in Kazakhstan. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

Results are not available in the source record.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Detection of biomarkers of translocation (time frame: 3-10 days). It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT06221293, which also lists 4 linked publications.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 19 Apr 2024.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in